Sernova Cell Pouch Bio-hybrid Organ (immunoprotected)

Sernova's first Cell Pouch is already in people, but it has a catch: recipients of donor islets must take lifelong anti-rejection drugs, which limits it to the sickest patients.¹ The "Bio-hybrid Organ" program is the next-generation answer to that problem — the same retrievable, under-the-skin pouch, but with each insulin-making islet wrapped in a microscopically thin "conformal coating" that shields it from immune attack locally, so that systemic immunosuppression can ideally be dropped.²³

How it works

The coating is a thin, cross-linked polyethylene glycol (PEG) hydrogel applied snugly around individual islets.⁴ It is engineered to be selectively permeable: small molecules — glucose, oxygen, nutrients, and the insulin the cells release — pass freely, while larger antibodies and immune cells are blocked from reaching the graft.⁴⁵ Because the gel hugs each islet rather than bundling many into one large capsule, the coated cluster stays small enough to fit in a well-vascularized site like the Cell Pouch, where oxygen supply is better.⁵ This addresses the two classic failure modes of older encapsulation: oxygen starvation and slow insulin diffusion.⁶

The evidence (preclinical)

This work comes mostly from Dr. Alice Tomei's lab at the University of Miami. In a landmark mouse study, fully mismatched (allogeneic) donor islets given a refined PEG/extracellular-matrix coating survived more than 100 days without any immunosuppression, with no immune-cell penetration and no T-cell priming — naked islets were rejected.⁷ A side-by-side comparison found that minimizing capsule size (as conformal coating does) is critical for normal, prompt insulin release.⁶ More recently, the coatings were shown to stay mechanically stable and selectively permeable out to 100 days in the lab,⁸ and a microfluidic device was built to coat islets uniformly and at scale — cutting graft volume 10- to 100-fold versus old microcapsules.⁹ Sernova has reported reversing diabetes in rodents with coated islets in the pouch, and in allogeneic animals achieving normal glucose with only a single selective immune agent rather than a full drug cocktail.³²

Immunosuppression, durability, eligibility, safety

The defining claim — protection without systemic anti-rejection drugs — has held in animals but has not been tested in humans.⁷² The retrievable pouch is a genuine safety feature: unlike islets infused into the liver, the whole implant can be removed and examined.¹¹⁰ Because no immunoprotected version has entered the clinic, human eligibility, durability against fibrosis, and safety remain unknown.¹¹

Trial phase and proximity to availability

This program is in preclinical development; there is no NCT trial and no IND for the immunoprotected, coating-based pouch as of mid-2026.¹¹ It is deliberately distinct from the donor-islet Cell Pouch (NCT03513939), which is in Phase 1/2 and does require immunosuppression.¹ The cell supply is intended to come from Sernova's partner Evotec, whose lab-grown (iPSC-derived) islet-like clusters would make the product off-the-shelf.¹²

What's coming

The near-term clinical step is the iPSC islets in the standard Cell Pouch — those trials were anticipated to begin in 2026, but initially still with immunosuppression.¹³ The conformal coating is the layer that would later remove the drugs; Sernova is finishing allogeneic optimization and building automated, GMP-grade coating equipment to reach the clinic.²³ If both pieces land — unlimited iPSC islets plus durable local immune protection — the result would be a true immunosuppression-free bio-hybrid organ.¹³ That remains a years-away goal, not a near-term product.

References

1. Sernova Biotherapeutics Inc. A Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch for Clinical Islet Transplantation (phase, design, immunosuppression, retrievability). ClinicalTrials.gov, NCT03513939. https://clinicaltrials.gov/study/NCT03513939 ↩ ↩² ↩³

2. Sernova Corp. Sernova Provides Development Update on Proprietary Cellular Conformal Coating Technology in Combination with Cell Pouch Device. Sernova press release (2023). https://sernova.com/press_releases/sernova-provides-development-update-on-proprietary-cellular-conformal-coating-technology-in-combination-with-cell-pouch-device/ ↩ ↩² ↩³ ↩⁴

3. Sernova Corp. Sernova Announces New Advancements of Conformal Coating Technology in Combination with the Cell Pouch System at the 2023 IPITA-IXA-CTRMS Joint Congress (Dr. Alice Tomei, University of Miami; Oct 30, 2023). Sernova press release (2023). https://sernova.com/press_releases/sernova-announces-new-advancements-of-conformal-coating-technology-in-combination-with-the-cell-pouch-system-at-the-2023-ipita-ixa-ctrms-joint-congress/ ↩ ↩² ↩³

4. deHaseth NH, Gonzalez GC, Stock AA, et al. Characterization of diffusivity and mechanical properties of polyethylene glycol hydrogel conformal coatings over time for application in beta cell replacement therapy for type 1 diabetes. Cell Mol Bioeng (2025), via PubMed. https://doi.org/10.1007/s12195-025-00878-7 ↩ ↩²

5. Vicinanza F, Mencarini T, Verderio F, et al. Microfluidic device for islet conformal coating with a polyethylene glycol-based hydrogel: innovating cell immunoprotection strategies in type 1 diabetes. Lab Chip (2025), via PubMed. https://doi.org/10.1039/d5lc00690b ↩ ↩²

6. De Toni T, Stock AA, Devaux F, et al. Parallel Evaluation of Polyethylene Glycol Conformal Coating and Alginate Microencapsulation as Immunoisolation Strategies for Pancreatic Islet Transplantation. Front Bioeng Biotechnol (2022), via PubMed. https://doi.org/10.3389/fbioe.2022.886483 ↩ ↩²

7. Manzoli V, Villa C, Bayer AL, et al. Immunoisolation of murine islet allografts in vascularized sites through conformal coating with polyethylene glycol. Am J Transplant (2017), via PubMed. https://doi.org/10.1111/ajt.14547 ↩ ↩²

8. deHaseth NH, Gonzalez GC, Stock AA, et al. Conformal hydrogel coatings remained functional and did not deteriorate over the 100-day period. Cell Mol Bioeng (2025), via PubMed. https://doi.org/10.1007/s12195-025-00878-7 ↩

9. Vicinanza F, Mencarini T, Verderio F, et al. Flow-focusing microfluidic platform achieving >10–100-fold reduction in graft volume relative to conventional microencapsulation. Lab Chip (2025), via PubMed. https://doi.org/10.1039/d5lc00690b ↩

10. Pepper AR, Pawlick R, Gala-Lopez B, et al. Diabetes Is Reversed in a Murine Model by Marginal Mass Syngeneic Islet Transplantation Using a Subcutaneous Cell Pouch Device (retrievable, prevascularized device rationale). Transplantation (2015), via PubMed. https://doi.org/10.1097/TP.0000000000000864 ↩

11. Sernova Biotherapeutics Inc. FY2025 Annual Information Form (conformal coating remains in preclinical development; distinct from the immunosuppression-dependent Cell Pouch). Sernova (2026). https://sernova.com/wp-content/uploads/2026/01/FY2025-Annual-Information-Form.pdf ↩ ↩²

12. Sernova Corp. Sernova and Evotec Enter into an Exclusive Global Strategic Partnership for iPSC-Based Beta Cell Replacement Therapy (off-the-shelf iPSC islets to supply the Cell Pouch). GlobeNewswire press release (May 17, 2022). https://www.globenewswire.com/news-release/2022/05/17/2444753/0/en/Sernova-and-Evotec-Enter-into-an-Exclusive-Global-Strategic-Partnership-for-iPSC-Based-Beta-Cell-Replacement-Therapy-to-Develop-and-Commercialize-a-Functional-Cure-for-Diabetes.html ↩

13. Sernova Biotherapeutics. Sernova Biotherapeutics Provides Positive Interim Data from Ongoing Phase 1/2 Clinical Trial of Cell Pouch Bio-hybrid Organ in Patients Living with Type 1 Diabetes (iPSC clinical trials anticipated to begin in 2026; "Bio-hybrid Organ" framing). Sernova press release (May 14, 2025). https://sernova.com/press_releases/sernova-biotherapeutics-provides-positive-interim-data-from-ongoing-phase-1-2-clinical-trial-of-cell-pouch-bio-hybrid-organ-in-patients-living-with-type-1-diabetes/ ↩ ↩²